Key result
This review highlights the complex causes, patient selection challenges, and emerging percutaneous therapies for tricuspid regurgitation in heart transplant recipients.
Why the study?
TR is common post cardiac transplantation and carries poor outcomes, but redo surgery carries prohibitive risk and emerging percutaneous therapies require careful patient selection given complex geometry and diverse etiologies.
Answers are grounded in this paper and cite their sources.
This review highlights the complex etiology of tricuspid regurgitation post-cardiac transplantation and discusses the potential role and patient selection for emerging percutaneous therapies.
Tricuspid regurgitation (TR) is common after cardiac transplantation and results in poorer outcomes. Transplant recipients are at high prohibitive risk for redo surgical procedures because of risks associated with a subsequent sternotomy, immunosuppression, and renal failure. Percutaneous therapies have recently become available and may be an option for transplant recipients. However, transplant recipients have complex geometry, and there is a myriad of causes of TR posttransplant. There is a need for careful patient selection for all percutaneous valve interventions, and this is particularly true in transplant recipients who suffer from right ventricular failure and rejection and may undergo repeated endomyocardial biopsies. Cognizant of the rapid developments in this space, this review article focuses on the causes of TR, treatments, and future therapies in heart transplantation recipients to the transplant cardiologist navigate this complex area.
No takes yet. Share an insight, caveat, or question.
Bart et al. (2023) conducted a review in Tricuspid regurgitation post cardiac transplantation. This review highlights the complex causes, patient selection challenges, and emerging percutaneous therapies for tricuspid regurgitation in heart transplant recipients.
Synapse has enriched 10 related papers. Consider them for comparative context: